Introduction
Methods
Patient recruitment and data collection
Single-nucleotide polymorphism (SNP) selection and genotyping
Bioinformatics analysis
Cell culture and transfection
Western blot analysis
Cell proliferation assay
Colony formation assay
Microarray analysis
Statistical analysis
Results
Characteristics | n (%) | HR (95% CI) |
p
|
---|---|---|---|
Age at diagnosis, median (IQR) | 66 (61–70) | 1.02 (0.99–1.04) | 0.149 |
PSA at diagnosis, median (IQR) | 11.1 (7.1–17.5) | 1.02 (1.01–1.02) | < 0.001 |
Pathologic Gleason score | |||
2–6 | 160 (35.3) | 1.00 | |
7–10 | 293 (64.7) | 2.19 (1.56–3.08) | < 0.001 |
Pathologic stage | |||
T1/T2 | 303 (67.2) | 1.00 | |
T3/T4/N1 | 148 (32.8) | 3.37 (2.51–4.52) | < 0.001 |
Surgical margin | |||
Negative | 241 (72.6) | 1.00 | |
Positive | 91 (27.4) | 2.80 (1.99–3.95) | < 0.001 |
Lymph node metastasis | |||
Negative | 433 (95.6) | 1.00 | |
Positive | 20 (4.4) | 13.4 (8.12–21.9) | < 0.001 |
Biochemical recurrence | 184 (40.2) | ||
Median follow-up, months | 54 |
Gene | SNP ID | Chromosome | Position | MAF | HWE | Alleles | BCR | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Additive | Dominant | Recessive | ||||||||||
p
|
q
|
p
|
q
|
p
|
q
| |||||||
CD8A
| rs1051386 | 2 | 86,865,584 | 0.182 | 0.382 | A > G | 0.626 | 0.317 | 0.438 | 0.274 | ‒ | ‒ |
CD8A
| rs13023213 | 2 | 86,875,454 | 0.074 | 0.523 | T > C | 0.336 | 0.254 | 0.367 | 0.254 | ‒ | ‒ |
ZAP70
| rs13034349 | 2 | 97,695,629 | 0.288 | 0.653 | C > T | 0.567 | 0.313 | 0.790 | 0.357 | 0.393 | 0.254 |
ZAP70
| rs7565744 | 2 | 97,708,501 | 0.167 | 0.225 | C > T | 0.390 | 0.254 | 0.320 | 0.254 | ‒ | ‒ |
ZAP70
| rs11686881 | 2 | 97,720,279 | 0.132 | 0.081 | C > T | 0.632 | 0.317 | 0.373 | 0.254 | ‒ | ‒ |
ICOS
| rs11883722 | 2 | 204,509,090 | 0.435 | 1.000 | G > A | 0.347 | 0.254 | 0.246 | 0.254 | 0.761 | 0.352 |
ICOS
| rs1559931 | 2 | 204,533,974 | 0.165 | 0.931 | G > A | 0.110 | 0.254 | 0.127 | 0.254 | ‒ | ‒ |
ICOS
| rs4675379 | 2 | 204,534,340 | 0.128 | 0.988 | G > C | 0.031 | 0.120 | 0.049 | 0.159 | ‒ | ‒ |
CD3E
| rs7928058 | 11 | 117,676,449 | 0.270 | 0.301 | G > T | 0.201 | 0.254 | 0.185 | 0.254 | 0.581 | 0.313 |
CD3E
| rs7480736 | 11 | 117,677,574 | 0.470 | 0.896 | C > T | 0.114 | 0.254 | 0.136 | 0.254 | 0.275 | 0.254 |
CD3E
| rs2231440 | 11 | 117,680,649 | 0.198 | 0.676 | G > A | 0.569 | 0.313 | 0.487 | 0.291 | ‒ | ‒ |
CD3D
| rs3212264 | 11 | 117,721,444 | 0.445 | 0.810 | C > A | 0.171 | 0.254 | 0.385 | 0.254 | 0.164 | 0.254 |
CIITA
| rs7196089 | 16 | 10,910,602 | 0.153 | 0.774 | G > A | 0.271 | 0.254 | 0.281 | 0.254 | ‒ | ‒ |
CIITA
| rs11074939 | 16 | 10,919,210 | 0.326 | 0.289 | G > A | 0.852 | 0.376 | 0.996 | 0.411 | 0.702 | 0.332 |
CIITA
| rs7404786 | 16 | 10,920,051 | 0.217 | 0.207 | C > G | 0.011 | 0.053 | 0.007 | 0.053 | 0.354 | 0.254 |
CD19
| rs2070961 | 16 | 28,856,974 | 0.211 | 0.751 | C > T | 0.878 | 0.379 | 0.231 | 0.254 | ‒ | ‒ |
TNFRSF13B
| rs4792800 | 17 | 16,785,892 | 0.410 | 0.522 | A > G | 0.009 | 0.053 | 0.258 | 0.254 | 0.001 |
0.019
|
TNFRSF13B
| rs12938061 | 17 | 16,786,880 | 0.210 | 0.775 | C > T | 0.636 | 0.317 | 0.495 | 0.291 | ‒ | ‒ |
TNFRSF13B
| rs4383187 | 17 | 16,788,634 | 0.278 | 0.855 | C > T | 0.923 | 0.389 | 0.698 | 0.332 | 0.331 | 0.254 |
Genotype |
n
| BCR | 5-year BFS |
p
|
q
| HR (95% CI) |
p
| HR (95% CI)a |
p
a
|
---|---|---|---|---|---|---|---|---|---|
AA | 163 | 61 | 57.8 | 1.00 | 1.00 | ||||
AG | 213 | 79 | 62.9 | 1.00 (0.72–1.40) | 0.980 | 1.10 (0.72–1.67) | 0.663 | ||
GG | 81 | 44 | 36.6 | 1.80 (1.22–2.66) | 0.003 | 1.88 (1.14–3.09) | 0.013 | ||
AG/GG vs. AA | 0.258 | 0.254 | 1.19 (0.88–1.62) | 0.263 | 1.27 (0.86–1.87) | 0.231 | |||
GG vs. AA/AG | 0.001 | 0.019 | 1.80 (1.28–2.53) | 0.001 | 1.78 (1.16–2.71) | 0.008 | |||
Trend | 0.009 | 0.053 | 1.31 (1.07–1.61) | 0.010 | 1.35 (1.04–1.75) | 0.022 |